The study of bacterial pathogens has advanced from culture on plates to basic biochemical studies; to sequencing reference genomes and attempting to ascribe those qualities to the whole species; to evaluating complete communities based on the universal marker of the 16S rRNA gene; to now sequencing all available nucleic acids in any sample to characterize the community as a whole. These types of scientific advances highlight that there are multiple layers of information within any sample, and to some extent we are only now beginning to be able to identify, categorize and understand the complex interactions of the host, pathogen and microbiome. In most cases, we can only now generate the data to examine these samples, but the detailed understanding of the significance of the data is lacking. We anticipate that in the future these microbiota and community data will be able to be modelled, understood and potentially used as either markers of disease, or diagnostics. This review provides a brief overview of the state of the use of microbiome studies using Travellers Diarrhea samples and what those studies have told us. More importantly these studies highlight what is remaining to be elucidated.
Introduction
There have been many studies on the microbiome, and there have been many studies of travellers' diarrhea (TD); however, there have been few studies that combine the examination of the host microbiome before, during or after TD. Searching of the PubMed databases with the key terms of "diarrhea" identifies 100 000 published studies, if the word "microbiome" is then added to the search, fewer than 700 publications are identified and those with the word "enteric" identify <100 studies with these key words ( Figure 1 ). The numbers of publications when the term enterotoxigenic Escherichia coli or ETEC, one of the leading causes of TD, decreases significantly. These facts highlight that this area of research is currently undeveloped. There are a number of studies that will combine the study of TD organisms and the microbiome that are underway, planned or are in the planning phases, for the near future.
In attempting to discuss the "microbiome" it is essential to first establish what types of analyses are going to be included, how they differ and what can be determined with each type of data. The vast majority of studies on the microbiome today use the prevalence of the universal marker gene for the 16S ribosomal RNA (16S rRNA) as a basis for comparison. The 16S rRNA gene is present in all bacteria, in at least one copy and there are extensive databases of these gene sequences for comparison. [1] [2] [3] Within the 16S rRNA gene there are sequence regions that are highly conserved, which allow for a universal set of primers to be used for amplification of the majority of the species, and there are variable regions that can be used to distinguish the species from each other. 1 In past studies the whole rRNA gene (2000 bp) was amplified, cloned, sequenced and compared with ever growing databases. 1 In recent years, the advent relatively inexpensive large-scale sequencing has opened the opportunity to examine greater numbers of these genes from complex mixtures. However, one must keep in mind that the determination of the presence or absence of a single gene in a mixture of potentially thousands of bacterial species, in complex samples such as human faeces, can have significant pitfalls. Many microbiome studies have been based on the sequencing and analysis of the 16S rRNA gene, but the limitations of these studies are beginning to be realized. The studies are limited to [4] [5] [6] and thus not all the bacterial community is equally represented. In addition, the 16S rRNA studies cannot distinguish between live and dead bacteria, which is a significant issue in a sample as complex as faecal matter, which is integrated with bacteria that are associated with food and water that is being ingested. Potentially most significant, the study of a single gene does not capture the variation that may be present among a single species, especially those that cause TD. For example, ETEC, can be a cause of TD, but the same16S rRNA gene(s) are present in the E. coli that cause TD, are also in the E. coli of the resident microbiome that cause no disease. Determining which E. coli is present and causing TD based on the 16S rRNA gene is impossible. In addition, these 16S rRNA gene-based studies cannot identify viral or parasitic organisms that may be involved in TD. This is especially important in cases where the pathogen is not identifiable, or the etiological agent is a mixture of bacterial, viral and/or fungal pathogens. Overall, the 16S rRNA gene provides the possibility to examine a complete community, but it is limited in terms of interpretation. One significant issue with the studies of the gastrointestinal microbiome is that the microbiome has been demonstrated to be in constant flux. The study mentioned above by David et al. 7 examined the variability of the microbiome associated with changes in diet. This study identified that even short term, <5 day, changes in the diet of participants resulted in significant alterations in the microbiome. One then can easily imagine that the impact of TD would also be significant on this community, with the clinical symptoms which include decreased transit times, increase fluid volumes and increased motility. A currently unpublished study in the Rasko group (unpublished) has identified that in ETEC infection there are significant changes among the gastrointestinal community structure between samples taken with relatively short time intervals (<6 h). While these changes in the microbial communities can be measured and catalogued, the deeper understanding of why these communities are changing and if they are changing in predictable ways has been elusive.
16S rRNA Based Studies
One of the first studies of the microbiome associated with TD was by Youmans et al. 8 In this study the research team examined subjects with ETEC (38 subjects], Norovirus (7 subjects], ETEC and Norovirus in the same individuals (17 subjects), people with TD, but no identified pathogen (43 subjects), healthy travellers (12 subjects), as well as samples from "normal healthy" individuals included from the Human Microbiome Project studies. [9] [10] [11] The authors define the alterations of the microbiome in association with TD, as a dysbiosis, or an imbalance of the microbiome. In all subjects the dybiosis of TD was associated with a high Firmicutes:Bacteroidetes ratios in the those who developed diarrhea, regardless of etiologic agent or presence of a pathogen. An additional interesting finding of the study was that there was no difference in the microbiome of those with TD or healthy travellers when compared with the samples from the Human Microbiome Project, suggesting that the simple act of travelling resulted in a dysbiotic microbiome that was indistinguishable from those with TD. As with the study by David et al. 7 the alteration of the food intake may result in changes in the microbiota, and when an individual travels, it is likely that they are not eating the same foods, at the same times, or in the same comfort level, as when they are at home. Additional factors are associated with travel that may alter the microbiome including, but not limited to, alterations in sleeping patterns, stress and increased contact with other humans. When microbiota analyses were completed by Youmans et al. 8 to examine the diversity of the community components, known as alpha and beta diversity, all samples from individuals with TD were similar, suggesting that TD results in similar changes in the microbiota, irrespective of the pathogen. While this study was one of the first to provide a detailed examination of the microbiota during TD, there are shortcomings. The samples to be examined were from naturally occurring disease, and as mentioned above this creates an inherent variability in the data due to differences in the host, pathogen and resident microbiome. In addition, the samples were collected cross sectionally, in that only a single sample was obtained from each individual. It has become evident in recent studies that with a significant amount of microbiome variation, as is identified in these samples, the identification of conclusive changes associated with TD in the microbiome from samples obtained from different individuals is difficult. 12 Also, when one wants to calculate the amount and significance of the microbiome variation, it is really advantageous to know what the starting microbiota is, so that one can identify what has been changed both in composition and relative abundance. These types of detailed comparisons can only be accomplished through longitudinal sampling and data analysis. There were also large numbers of samples in this study that were from TD without any known pathogen, so the interpretation of the microbiome data from these studies, and comparison to TD samples with a known pathogens is difficult. In addition, while these studies were not meant to identify novel pathogens, these types of TD samples provide the opportunity to identify novel associations of TD and previously unknown pathogens, or isolates of species not previously known as pathogens. This will require further study to conclusively identify these types of high-level associations and much more detailed functional work to define the actual pathogen or group of species/isolates that are associated with TD. The comparison of the Human Microbiome Project data, 10, 11 from Western populations eating a Western diet to the microbiomes from individuals in Bangladesh is a comparison fraught with issues. There are many factors that could impact the microbiome comparisons, including, but not limited to the host genetic makeup, diet, nutritional status, pathogen burden as well as previous pathogen exposures. Each of these factors is not addressed when these microbiome comparisons were completed, but in future studies they will need to be considered. An additional, more recent and focused study of the 16S rRNA genes from microbial communities with ETEC, a common TD agent, was published by Pop et al. 13 This study has taken into account some of the things that have been learned about the study of the microbiome during disease in the Global Enteric Multisite Study. 14 They utilized longitudinal samples of a human ETEC challenge using 12 volunteers infected with the ETEC prototype isolate H10407. Using a challenge study design for ETEC provides the ability to control many aspects of the infection process that in a natural setting are uncontrollable, including pathogen, variable virulence between isolates, dose, delivery vehicle and carefully selected hosts for lack of previous exposure to the pathogen, lack of antibiotic use in the recent past, as well as potential blood group antigens, all which can impact the outcome in diarrheal diseases. 15 Only 5 of 12 subjects progressed to diarrhea in this study, and among those five, the changes in the microbiome were significant and could be correlated to an increased read count for E. coli, as well as a quantitative PCR assay that was developed, which was similar to another quantitative PCR assay this group has developed for Shigella. 16 An additional aspect of this study was the examination of samples after the introduction of an antibiotic, Ciprofloxacin, which also resulted in significant changes in the microbiome, as one would have expected. Interestingly, the changes in the microbiome observed with the introduction of ETEC or antibiotics, were not consistent in all the patients and in some cases were indistinguishable from each other irrespective of pathogen or antibiotic. Additional longer-term samples, 3 months after the initial challenge study, suggested that the majority of individuals returned to a similar microbiome community state from which they originated. Overall, this study is one of the most comprehensive 16S rRNA TD pathogen based studies to date.
Recovery-Based Studies
While the use of prospective-based challenge studies are an optimal controlled situation in examining the changes of the microbiome in controlled conditions, most studies completed on the topic of TD and microbiome, or diarrhea and the microbiome in general are termed "recovery studies". This term means that the subjects are exhibiting clinical symptoms and arrive to some type of healthcare facility where samples are acquired, then they begin treatment and more samples are being acquired as antibiotic treatment progresses. One of those studies is by Monira et al., 17 in which the authors examined the changes in the diarrheal-associated microbiome after Vibrio cholerae infection.
While not a traditional TD pathogen, V. cholerae has a mechanism of action, namely the cholera toxin, which is very similar to the heat-labile toxin of ETEC, one of the most common TD agents. This study contained nine adult subjects that presented to the hospital with diarrhea within the previous 10 h. The study examines the changes in the pathogen burden, as well as the microbial community structure in the early acquired time points of associated with diarrhea, but also identifies that while there are some trends in the data, it was difficult to correlate changes in the community structure with the infectious process or antibiotic treatment, which most subjects underwent almost immediately upon arrival at the hospital, as per the standard of care. In addition, it is well recognized that not everyone has the same initial gastrointestinal microbiota, and as such what may look like an alteration in one subject is "normal" in others and vice versa. The greatest weakness of the recovery-based studies is that there is no knowledge of the TD pathogen, dose or what the initial microbiome state was, and so defining a "difference in the microbiome" is virtually impossible. In addition, many of these types of studies are conducted, not in western populations of travellers, but rather among the populations in countries where these pathogens are endemic. It is unknown at this time what impact these factors will have on the microbiome and the alterations of the microbiome after a diarrheal event and how to compare these changes with those in western travellers. There are some research groups that assert that all diarrhea, TD included, will have a similar impact on the microbiome, whereas others content that the microbiome changes are pathogen specific. Many more studies will be required to determine which factors are important in the study of TD-associated microbiome changes. In addition, the relevance of studies in endemic populations vs challenge studies to be completed on western volunteers may also significantly impact the outcomes, and may not be directly comparable. Currently, we do not have sufficient data to address these factors from either controlled challenge or TD studies. From the recovery-based studies that have been completed it appears that the microbiomes of each individual respond differently to TD pathogens. This is most likely why a range of clinical illness are observed when large numbers of individuals ingest the same contaminated food product, but some get very ill, others get mildly ill and some even have no symptoms at all. The recovery-based studies provide us a window into what is happening during the disease and resolution/treatment phases, but leave us blind as to how these states are arrived upon.
Metagenomic Studies
It is anticipated that the large-scale systems biology approaches will dominate the future landscape of studies to examine the host:pathogen:microbiome interactions. Using ETEC as a primary example of the evolution of the study of Travellers Diarrhea. ETEC was the first E. coli pathovar to have the virulence genes cloned into another E. coli isolate in the late 1970s, with the heat stable toxin in 1976 18 and 2 years later the heatlabile toxin. 19 One recent study has utilized metagenomics of individuals that were entering the diarrhea clinic in Bangladesh. 20 In this study, individuals that entered the clinic were identified as having V. cholerae or ETEC and faecal samples were collected as treated with antibiotics commenced. The faecal samples were subjected to metagenomic sequencing that allowed the interrogation of all of the nucleic acids that were included in the sample. 21, 22 It is important to note that while the current studies have focused on the examination of only the bacteria in these samples, the process of metagenomic sequencing will also capture the host, fungal and viral components of the sample. This is critical in understanding the community as a whole in terms of co-infection, as well as susceptibility models of infection. It has been clearly demonstrated by the work of the Pfeiffer group and others that many enteric viruses require a bacterial microbiome for infection. [23] [24] [25] The whole metagenomic approach provides us the possibility to examine these previously undescribed factors in context of the complete sample. The study by David et al. 20 provided unprecedented insights into the dynamics of the microbial community, and provided novel insights into the re-establishment of the microbial community after a diarrheal episode. It was thought that the processes of V. cholerae and ETEC diarrhea and impact on the microbiome, as well as the resolution would be similar since the diarrhea in both cases is thought to be primarily toxin mediated. However, David et al.
20
identified many additional factors that appeared to be involved in the microbial succession after diarrhea including oxygen levels, available carbohydrate sources, as well as the phage communities that are associated with these pathogens. The interactions of the pathogen with the host and the resident microbiota are complex and not well understood. While this study was limited by the relatively small number of individuals in the study, as well as the potential for variation related to different TD-associated pathogens and pathogenic mechanisms. For example, Sahl et al. 26 identified, again in a limited culture study, that by isolating just 10 colonies from a culture plate of 12 adults with ETEC infection, 15% of the subjects harboured more than one genomically distinct ETEC isolate, with variable virulence factor profiles. In that study, all subjects had severe diarrhea, but it was impossible for the research group to conclusively assign the etiological agent that caused the diarrhea from the mixtures of potentially pathogenic ETEC isolates. It was previously thought that the 16S rRNA gene analysis was difficult, however the amount of data generated by whole shotgun metagenomics is order of magnitudes greater than the 16S data, and more complex in terms of the potential interactions. Identifying, explaining and then validating the results from metagenomic data are complex, and if possible will require intimate knowledge of the organism and isolates in that particular sample. Recent attempts have been made to extensively culture and characterize the organisms in the gastrointestinal tract and provide a resource for the community to access these data and isolates. 27, 28 Further efforts of this nature will facilitate our understanding of the microbiome in general and place metagenomic studies into context with the functional studies of TD.
Conclusions
While the described studies on the pathogen and community dynamics are often limited in scope and number of subjects, the potential to use these data as a model to being to understand and develop potential diagnostics based on the community structure, with the 16S rRNA or metagenomic sequencing, or in the future with metatranscriptomics and metabolomics are possible. However, in order for there to be a deeper understanding of the changes in the microbiome and what factors are important in the changes of the microbiome, large scale controlled pathogen challenge studies are the most controlled studies to complete with the greatest likelihood of success of identification of the important features of the microbiome associated with TD. By examining the microbiome after disease symptoms are present, as many studies attempt to do, there are many variables including, pathogen, pathogen dose, host microbiome prior to infection and time to arrival at a health care facility to discern which factors are important and which may by a byproduct of the TD process. Since it is known that the microbiome is dynamic and constantly changing, each of the identified factors, and many more unknown factors will undoubtedly impact the broad utility of any generated data, as well as facilitate or prevent comparison between studies. Controlled challenge studies can normalize the pathogen, infectious dose, as well as closely monitor symptomology. Through these types of studies there will be enough of a controlled system to begin to understand the interactions of the host, pathogen and microbiota; however, there are still limitations to the controlled challenge studies. Riddle and Connor 29 have recently reviewed the microbiome and TD in detail, and in that review they have highlighted the need for the study of the microbiome of actual travellers who naturally get TD. While this is an excellent approach, our current understanding of the host:pathogen:microbiome interactions are limited, and there are many variables when attempting to examine the microbiome in "real-world" situations. As has been previously outlined in Youmans et al., 8 which identified travel itself as a significant factor in altering the microbiome. In addition to the process of travel, there are multiple pathogens that have been identified to be associated with TD (enterotoxigenic E coli, Shigella species, Campylobacter species, Norovirus and other viral vectors), as well as studies that suggest that a significant number of TD cases have no known cause, 8 genetic variation in terms of the isolate that can/will infect any one person, dose, delivery vehicle (food, water, other, etc.), resident microbiome, host genetics, host health, etc. Even in the most controlled situation, a challenge trial, with a single pathogen at a defined dose, and with selected hosts, the research community has had little success in identifying a microbiome that is "protective" or "susceptible" or correlating the patterns of change in the microbiome associated with TD and after TD with treatments of antibiotics. However, these challenge studies have been completed on a relatively small number of subjects, and larger studies are required to generate sufficient data for more conclusive findings. It is agreed that the real-world situations would be more informative and relevant; however, the complexity of those studies and our current lack of understanding of the microbiome and the interactions would most likely result in the generation of data that we cannot comprehend or model to significantly increase our understanding of the TD process.
